The Indian Council Research ( lCMR ) on Saturday has issued revised guidelines or releases a series of new protocol for CORONAVIRUS.
The health authority may drop HYDROXYCHLOROQUINE, popularly called HCQ , from the protocol due to increasing doubt over its effectiveness of the drug for the treatment of COVID-19 patients.
The ICMR , the Apex Health Research Institution, has been mulling over the use of RAMDESIVIR, an antiviral drug which has shown improvement in CORONAVIRUS patients in formal clinical trials.
On Wednesday the director of ICMR Dr. Balram Bhargana said that there has been a revision in the treatment protocol for clinical management of COVID-19 patients. “We will put up details on the ICMR’s website on Thursday said Dr. Balram and on Saturday the ICMR has issued revised guidelines or protocol for the treatment of COVID-19 patients.
The ICMR revised the guidelines to expand use of this anti – malarial drug as a preventive treatment against COVID-19.
” The disease is evolving and now that we know that HCQ is not working it should be removed from the treatment protocol , ” a person familiar with the development told the newspaper. ” Rather other drug which have proved to be efficacious should be added into the new protocol.
Recently, researchers also reported in the Journal Nature that treatment with the antiviral drug REMDESIVIR has been found to reduce viral load and present lung disease in macaques infected with SARS-COV-2.
The study supported the early use of REMDESIVIR treatment in patients with COVID-19 to prevent progression to pneumonia.
Currently, REMDESIVIR is allowed for emergency compassionate use in treating severely – ill COVID-19 patient and it is likely to be part of the revised protocol.
REMDESIVIR was granted emergency use authorisation by the US food and drug administration last month and has received approval by Japanese Health Regulators. According to sources, with the government set to produce the drug, Indian Companies are looking at manufacturing biosimilars. “So far, hospitals do not have the drug , ” said intensivists at various dedicated COVID hospitals.
According to reports US – based Gilead Sciences has given a voluntary licence for production of REMDESIVIR to four companies in the country. Research on the efficacy of REMDESIVIR in the treatment of COVID-19 is part of WHO’s solidarity trial.
In a recent study in the New England Journal Of Medicine , preliminary findings supported the use of REMDESIVIR for patients who are hospitalized with COVID-19 and require supplemental oxygen therepy.
However, given high mortality despite the use of REMDESIVIR, it is not likely to be sufficient with an antiviral drug alone is not likely to be sufficient and future strategies should evaluate anti – viral agents in combination with other therapeutic approaches to improve patients outcomes in COVID-19, the NEJM study said.